Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This board is deteriorating because of the absence of concrete news from the company. Wild swings in speculative time frames are now the norm on the board....summer, fall, winter, what have you.
It is hard to even guage the truth on anything, even MSA......
For the last time....I'm long 35K shares...........and it's sitting in the red....
This is a position I don't trade in and out of so I am happy to wait for a recovery...
I just don't feel compelled to drink the koolaid and say what I feel...
If XXII is not thrilling me it's my right as a shareholder to air those thoughts....
I don't like how the whole pump surrounding the uplisting was constructed....
I've already stated that my position is 35K shares long....
The level of misunderstanding on this board goes beyond words....the fact that someone needed to explain the Delaware address was simply the registered agent...the legal entity is a Delaware LLC...
It's laughable folks start connecting dots to Dupont in Wilmington, etc....
Which one is it? the facts or as you suggest in your message....just your opinion.....
you may want to edit the ridiculous contradiction
search the delaware sos and you get a hit for this new llc
AVTI on the move today.....
Perker,
I've seen folks like you on other boards........the supportive long who drops in quickly with subtle messages of big things on the horizon.....leaving just as quick to avoid any direct engagement with other posters or those with contrary views. The role of that character is a vintage one in every stock pump and dump that has gone up in flames and left countless with worthless shares...
Be clear, I am not suggesting you are filling that role here....only that your posting style is eerily reminiscent of many who came before that had illicit intentions as part of a wider scheme in a stock....it's happened before and will happen again.....
ASCO has granted AE37 a rare exception....this is very likely great news.....as something is obviously happening in advance of the May abstract release date. A formal exception is very rare....
Abstract Announcements and Exceptions
Confidentiality Policy Exceptions
According to ASCO's Confidentiality Policy, each abstract submitted to the Annual Meeting is confidential from the time of submission until the date and time when ASCO makes the abstract publicly available. Under rare, extenuating circumstances requiring a formal application, abstracts may receive an Exception to ASCO’s Confidentiality Policy. These formal Exceptions require approval by ASCO prior to the information being made public.
The following abstracts have received formal Exceptions to ASCO’s Confidentiality Policy for the 2014 ASCO Annual Meeting:
Abstract #613
"Comparison of recurrent and nonrecurrent breast cancer patients undergoing AE37 peptide vaccine therapy."
Abstract #638
"Primary analysis of the prospective, randomized, single-blinded phase II trial of AE37 vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients."
Abstract #6005
Final analysis: A randomized, blinded, placebo (P)-controlled phase III study of adjuvant postoperative lapatinib (L) with concurrent chemotherapy and radiation therapy (CH-RT) in high-risk patients with squamous cell carcinoma of the head and neck (SCCHN).
Abstract #8000
"Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial."
Abstract #LBA8006^
"REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy."
Abstract #9008a
"Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma."
Abstract #9011^
“COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma.”
GNBT time coming....
see the first two AE37 items......
Abstract Announcements
Abstract Announcements and Exceptions
Confidentiality Policy Exceptions
According to ASCO's Confidentiality Policy, each abstract submitted to the Annual Meeting is confidential from the time of submission until the date and time when ASCO makes the abstract publicly available. Under rare, extenuating circumstances requiring a formal application, abstracts may receive an Exception to ASCO’s Confidentiality Policy. These formal Exceptions require approval by ASCO prior to the information being made public.
The following abstracts have received formal Exceptions to ASCO’s Confidentiality Policy for the 2014 ASCO Annual Meeting:
Abstract #613
"Comparison of recurrent and nonrecurrent breast cancer patients undergoing AE37 peptide vaccine therapy."
Abstract #638
"Primary analysis of the prospective, randomized, single-blinded phase II trial of AE37 vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients."
Abstract #6005
Final analysis: A randomized, blinded, placebo (P)-controlled phase III study of adjuvant postoperative lapatinib (L) with concurrent chemotherapy and radiation therapy (CH-RT) in high-risk patients with squamous cell carcinoma of the head and neck (SCCHN).
Abstract #8000
"Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial."
Abstract #LBA8006^
"REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy."
Abstract #9008a
"Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma."
Abstract #9011^
“COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma.”
The 8k reads well and succeeds at conveying that this company has big possibilities. Problem is that it is all based on hope at this point.....
Chardan will likely not win investment house of the year with that stubborn reiteration of $9 target. If it were me, the analyst would be booted out as it's outrageous and reckless to claim such a speculative stock as pick of the year...
AVTI...needs more filings or news.........is it coming?
BTW...Chardan has been very quiet....its quite likely they will not reiterate their $9 target again...
I assume that the long holiday weekend has given Big Stocks more time to ponder on the mixed shelf, so looking forward to their special brand of speculating....
So they will be engaging in the tricks of triple Zero pinkies. Spin off lol
I have an open mind on this shelf....just interested hearing about the 'speculating' that will assuredly be done by Big Stocks regarding the filing and assuredly it will be a ridiculous.
THE TRUTHFUL INVESTORS definition is 'dilution'
I gather you folks are stubbornly opening your eyes.....you'll need them as I expect the pump sheet to announce its ending coverage of this lemon based on the unanticipated filing...chalked up to a disappointment in management forthrightness...
Looking forward to Monday.....should be hot
The only thing I find sickening is that mgt. fueled the run into the uplisting with continuous news releases. But now they've gone silent which is the kiss of death for a stock followed by so few. They played the game and manipulated. No annual meeting news...no MSA.....no reiteration by Chardan....no lengthy fluff by Big Stocks.....hmmm....
very close here to a big break...
Very promising here.....
going down in flames as expected and predicted
waiting for news from an annual meeting....LOL
I said this was a pump and it clearly is being proved to be....
update = wild speculation nothing more
Has Big Stock reiterated their believe in XXII as an investment. I have heard since the collapse they are simply speculating on business developments and steering clear of rendering an opinion of XXII as an investment nor stating their stance hasn't change. Folks have told me, like it or not, they are choosing their words more carefully to hedge against the irresponsible pumping and targets that were thrown out during the uplist pump.
Of course it blows it away....it's called wild and reckless speculation imo
I have not heard anything new nor should we coming out of an annual meeting which is just a formality....
But leave it to folks to spin ever word into newer and grander international opportunities.
The bottom line for me is this is a lot of smoke...so to speak...
no MSA ..no nothing yet..
I imagine there was enough innuendo for Big Stock to get back to some further speculating and Chardan to reiterate target...
Again your recap while appreciated can be interpreted in various ways. I interpret it that we are still a long ways from getting real traction and real investor interest. 3 months from now they head out on a road show with hopes of convincing someone to invest. This is a very long term investment and I wonder why folks follow it rabidly on a daily basis.....
Clearly they are a real company with real IP.....but they are not well positioned to succeed w/o the gov't. paving the way. Those are not necessarily the odds I would prefer to invest in nor do they come without great risk of when or even ever will the necessary approval occur. With that said I hold my almost 35K shares strong....
That's all well and good....they need to monetize something somewhere and execute on one market opportunity....It all reads well but means jack without sales.....
Oh please....don't tell me you are going to latch on to that statement re: MSA....
They could say it might happen from now to eternity and no guess is better than any other....it's a joke there is no guarantee...
Desperate no interest in the states
If I had to speculate on the meeting it would be that there were enough tidbits to keep the speculators speculating for the foreseeable future......
Underwhelming meeting
is what I expect to hear...
Let me say I have strong hands but believe the flow of news was highly manipulated...
Chardan, Big Stocks and XXII lost my interest when they pumped the heck out of this as a lead in to the uplisting and profit taking........that is the work of an OTC not a supposed big board stock.